Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Topoisomerase I inhibitor, irinotecan, depletes regulatory T cells and up-regulates MHC class I and PD-L1 expression, resulting in a supra-additive antitumor effect when combined with anti-PD-L1 antibodies.

Iwai T, Sugimoto M, Wakita D, Yorozu K, Kurasawa M, Yamamoto K.

Oncotarget. 2018 Jul 31;9(59):31411-31421. doi: 10.18632/oncotarget.25830. eCollection 2018 Jul 31.

2.

Visualization of 57Fe-Labeled Heme Isotopic Fine Structure and Localization of Regions of Erythroblast Maturation in Mouse Spleen by MALDI FTICR-MS Imaging.

Kihara M, Matsuo-Tezuka Y, Noguchi-Sasaki M, Yorozu K, Kurasawa M, Shimonaka Y, Hirata M.

J Am Soc Mass Spectrom. 2017 Nov;28(11):2469-2475. doi: 10.1007/s13361-017-1768-y. Epub 2017 Aug 17.

3.

Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model.

Masuda C, Yanagisawa M, Yorozu K, Kurasawa M, Furugaki K, Ishikura N, Iwai T, Sugimoto M, Yamamoto K.

Int J Oncol. 2017 Aug;51(2):425-434. doi: 10.3892/ijo.2017.4036. Epub 2017 Jun 8.

4.

The effect of frequency of C.E.R.A. administration on the contribution of dietary iron for erythropoiesis.

Matsuo-Tezuka Y, Noguchi-Sasaki M, Kurasawa M, Yorozu K, Shimonaka Y.

Int J Hematol. 2017 Jul;106(1):60-70. doi: 10.1007/s12185-017-2215-3. Epub 2017 Mar 14.

PMID:
28293818
5.

Importance of Bevacizumab Maintenance Following Combination Chemotherapy in Human Non-small Cell Lung Cancer Xenograft Models.

Ishikura N, Yanagisawa M, Noguchi-Sasaki M, Iwai T, Yorozu K, Kurasawa M, Sugimoto M, Yamamoto K.

Anticancer Res. 2017 Feb;37(2):623-629.

PMID:
28179309
6.

Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model.

Iwai T, Sugimoto M, Harada S, Yorozu K, Kurasawa M, Yamamoto K.

Oncol Rep. 2016 Aug;36(2):626-32. doi: 10.3892/or.2016.4902. Epub 2016 Jun 22.

7.

Efficacy estimation of erythropoiesis-stimulating agents using erythropoietin-deficient anemic mice.

Suzuki N, Sasaki Y, Kato K, Yamazaki S, Kurasawa M, Yorozu K, Shimonaka Y, Yamamoto M.

Haematologica. 2016 Sep;101(9):e356-60. doi: 10.3324/haematol.2015.140814. Epub 2016 May 31. No abstract available.

8.

Quantitative analysis of dietary iron utilization for erythropoiesis in response to body iron status.

Matsuo-Tezuka Y, Noguchi-Sasaki M, Kurasawa M, Yorozu K, Shimonaka Y.

Exp Hematol. 2016 Jun;44(6):491-501. doi: 10.1016/j.exphem.2016.02.005. Epub 2016 Feb 19.

PMID:
26911670
9.

Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.

Yoshimura Y, Kurasawa M, Yorozu K, Puig O, Bordogna W, Harada N.

Cancer Chemother Pharmacol. 2016 Mar;77(3):623-8. doi: 10.1007/s00280-016-2977-y. Epub 2016 Feb 5.

PMID:
26849637
10.

Reduction of a marker of oxidative stress with enhancement of iron utilization by erythropoiesis activation following epoetin beta pegol administration in iron-loaded db/db mice.

Noguchi-Sasaki M, Sasaki Y, Matsuo-Tezuka Y, Yasuno H, Kurasawa M, Yorozu K, Shimonaka Y.

Int J Hematol. 2016 Mar;103(3):262-73. doi: 10.1007/s12185-015-1929-3. Epub 2016 Jan 6.

PMID:
26739261
11.

Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification.

Furugaki K, Fukumura J, Iwai T, Yorozu K, Kurasawa M, Yanagisawa M, Moriya Y, Yamamoto K, Suda K, Mizuuchi H, Mitsudomi T, Harada N.

Int J Cancer. 2016 Feb 15;138(4):1024-32. doi: 10.1002/ijc.29848. Epub 2015 Oct 13.

12.

Asymmetrically fused polyoxometalate-silver alkynide composite cluster.

Kurasawa M, Arisaka F, Ozeki T.

Inorg Chem. 2015 Feb 16;54(4):1650-4. doi: 10.1021/ic502644v. Epub 2015 Jan 13.

PMID:
25586879
13.

Gas-forming liver abscess associated with rapid hemolysis in a diabetic patient.

Kurasawa M, Nishikido T, Koike J, Tominaga S, Tamemoto H.

World J Diabetes. 2014 Apr 15;5(2):224-9. doi: 10.4239/wjd.v5.i2.224.

14.

Novel neuromuscular electrical stimulation system for treatment of dysphagia after brain injury.

Toyama K, Matsumoto S, Kurasawa M, Setoguchi H, Noma T, Takenaka K, Soeda A, Shimodozono M, Kawahira K.

Neurol Med Chir (Tokyo). 2014;54(7):521-8. Epub 2014 Mar 27.

15.

Epoetin beta pegol (C.E.R.A.) promotes utilization of iron for erythropoiesis through intensive suppression of serum hepcidin levels in mice.

Sasaki Y, Noguchi-Sasaki M, Matsuo-Tezuka Y, Matsumoto-Omori Y, Kurasawa M, Yorozu K, Shimonaka Y.

Int J Hematol. 2014;99(5):561-9. doi: 10.1007/s12185-014-1554-6. Epub 2014 Mar 13.

PMID:
24623262
16.

Human beta defensin-1 regulates the development of tight junctions in cultured human epidermal keratinocytes.

Goto H, Hongo M, Ohshima H, Kurasawa M, Hirakawa S, Kitajima Y.

J Dermatol Sci. 2013 Aug;71(2):145-8. doi: 10.1016/j.jdermsci.2013.04.017. Epub 2013 Apr 26. No abstract available.

PMID:
23712061
17.

Predictive markers of capecitabine sensitivity identified from the expression profile of pyrimidine nucleoside-metabolizing enzymes.

Yasuno H, Kurasawa M, Yanagisawa M, Sato Y, Harada N, Mori K.

Oncol Rep. 2013 Feb;29(2):451-8. doi: 10.3892/or.2012.2149. Epub 2012 Nov 27.

PMID:
23229803
18.

Highly fluorescent slipped-cofacial phthalocyanine dimer as a shallow inclusion complex with α-cyclodextrin.

Morisue M, Ueda S, Kurasawa M, Naito M, Kuroda Y.

J Phys Chem A. 2012 May 31;116(21):5139-44. doi: 10.1021/jp302640j. Epub 2012 May 18.

PMID:
22578193
19.

Biomarkers for antitumor activity of bevacizumab in gastric cancer models.

Yamashita-Kashima Y, Fujimoto-Ouchi K, Yorozu K, Kurasawa M, Yanagisawa M, Yasuno H, Mori K.

BMC Cancer. 2012 Jan 25;12:37. doi: 10.1186/1471-2407-12-37.

20.

Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models.

Yamashita-Kashima Y, Iijima S, Yorozu K, Furugaki K, Kurasawa M, Ohta M, Fujimoto-Ouchi K.

Clin Cancer Res. 2011 Aug 1;17(15):5060-70. doi: 10.1158/1078-0432.CCR-10-2927. Epub 2011 Jun 23.

21.

Tight junction regulates epidermal calcium ion gradient and differentiation.

Kurasawa M, Maeda T, Oba A, Yamamoto T, Sasaki H.

Biochem Biophys Res Commun. 2011 Mar 25;406(4):506-11. doi: 10.1016/j.bbrc.2011.02.057. Epub 2011 Feb 15.

PMID:
21329672
22.

Perturbation of lamellar granule secretion by sodium caprate implicates epidermal tight junctions in lamellar granule function.

Kuroda S, Kurasawa M, Mizukoshi K, Maeda T, Yamamoto T, Oba A, Kishibe M, Ishida-Yamamoto A.

J Dermatol Sci. 2010 Aug;59(2):107-14. doi: 10.1016/j.jdermsci.2010.06.001. Epub 2010 Jun 16.

PMID:
20654784
23.

Bevacizumab improves the delivery and efficacy of paclitaxel.

Yanagisawa M, Yorozu K, Kurasawa M, Nakano K, Furugaki K, Yamashita Y, Mori K, Fujimoto-Ouchi K.

Anticancer Drugs. 2010 Aug;21(7):687-94. doi: 10.1097/CAD.0b013e32833b7598.

PMID:
20559127
24.

Regulation of tight junction permeability by sodium caprate in human keratinocytes and reconstructed epidermis.

Kurasawa M, Kuroda S, Kida N, Murata M, Oba A, Yamamoto T, Sasaki H.

Biochem Biophys Res Commun. 2009 Apr 3;381(2):171-5. doi: 10.1016/j.bbrc.2009.02.005. Epub 2009 Feb 10.

PMID:
19338770
25.

Effect of RNA interference of tight junction-related molecules on intercellular barrier function in cultured human keratinocytes.

Yamamoto T, Saeki Y, Kurasawa M, Kuroda S, Arase S, Sasaki H.

Arch Dermatol Res. 2008 Oct;300(9):517-24. doi: 10.1007/s00403-008-0868-8. Epub 2008 Jun 17.

PMID:
18560860
26.

Relationship between expression of tight junction-related molecules and perturbed epidermal barrier function in UVB-irradiated hairless mice.

Yamamoto T, Kurasawa M, Hattori T, Maeda T, Nakano H, Sasaki H.

Arch Dermatol Res. 2008 Feb;300(2):61-8. Epub 2007 Dec 7.

PMID:
18064478
27.

Adult-onset Still's disease in a patient over 80 years old successfully treated with low-dose methotrexate therapy.

Kurasawa M, Kotani K, Kurasawa G, Shida K, Yamada S, Tago T.

Age Ageing. 2007 Jan;36(1):104-6. Epub 2006 Dec 6.

PMID:
17158115
28.

Spectral heterogeneity of honeybee ommatidia.

Wakakuwa M, Kurasawa M, Giurfa M, Arikawa K.

Naturwissenschaften. 2005 Oct;92(10):464-7. Epub 2005 Oct 28.

PMID:
16136295
29.

Causes of chronic retention of urine in the primary care setting.

Kurasawa G, Kotani K, Kurasawa M, Takama N, Orimo K.

Intern Med. 2005 Jul;44(7):761-2. No abstract available.

30.

Sexual dimorphism of short-wavelength photoreceptors in the small white butterfly, Pieris rapae crucivora.

Arikawa K, Wakakuwa M, Qiu X, Kurasawa M, Stavenga DG.

J Neurosci. 2005 Jun 22;25(25):5935-42.

31.
32.

Cholinergic and dopaminergic mechanisms involved in the recovery of circadian anticipation by aniracetam in aged rats.

Tanaka Y, Kurasawa M, Nakamura K.

Pharmacol Biochem Behav. 2002 May;72(1-2):45-53.

PMID:
11900768
33.

Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism.

Nakamura K, Kurasawa M.

Eur J Pharmacol. 2001 May 18;420(1):33-43.

PMID:
11412837
34.

Aniracetam restores motivation reduced by satiation in a choice reaction task in aged rats.

Nakamura K, Kurasawa M.

Pharmacol Biochem Behav. 2001 Jan;68(1):65-9.

PMID:
11274709
35.

CD4(+)-T-Cell-mediated resistance to systemic murine candidiasis induced by a membrane fraction of Candida albicans.

Mizutani S, Endo M, Ino-Ue T, Kurasawa M, Uno Y, Saito H, Onogi K, Kato I, Takesako K.

Antimicrob Agents Chemother. 2000 Oct;44(10):2653-8.

36.

Recovery of diminished mealtime-associated anticipatory behavior by aniracetam in aged rats.

Tanaka Y, Kurasawa M, Nakamura K.

Pharmacol Biochem Behav. 2000 Aug;66(4):827-33.

PMID:
10973522
37.

Serotonergic mechanisms involved in the attentional and vigilance task performance of rats and the palliative action of aniracetam.

Nakamura K, Kurasawa M.

Naunyn Schmiedebergs Arch Pharmacol. 2000 May;361(5):521-8.

PMID:
10832606
38.
39.

Immunization with the Candida albicans membrane fraction and in combination with fluconazole protects against systemic fungal infections.

Mizutani S, Endo M, Ino-Ue T, Kurasawa M, Uno Y, Saito H, Kato I, Takesako K.

Antimicrob Agents Chemother. 2000 Feb;44(2):243-7.

40.

Differential expression of C-protein isoforms in developing and degenerating mouse striated muscles.

Kurasawa M, Sato N, Matsuda A, Koshida S, Totsuka T, Obinata T.

Muscle Nerve. 1999 Feb;22(2):196-207.

PMID:
10024132
41.

Apomorphine-induced hypoattention in rats and reversal of the choice performance impairment by aniracetam.

Nakamura K, Kurasawa M, Tanaka Y.

Eur J Pharmacol. 1998 Jan 26;342(2-3):127-38.

PMID:
9548378
42.

Assembly of cardiac C-protein during myofibrillogenesis in myogenic cells in culture.

Koshida S, Kurasawa M, Yasuda M, Sato N, Obinata T.

Cell Struct Funct. 1995 Aug;20(4):253-61.

43.

The histidine interruption of an alpha-helical coiled coil allosterically mediates a pH-dependent ligand dissociation from macrophage scavenger receptors.

Doi T, Kurasawa M, Higashino K, Imanishi T, Mori T, Naito M, Takahashi K, Kawabe Y, Wada Y, Matsumoto A, et al.

J Biol Chem. 1994 Oct 14;269(41):25598-604.

44.

3-O-methyldopa attenuates the effects of Madopar on the haloperidol-induced cataleptic behavior and the locomotor activity in the mouse.

Himori N, Tanaka Y, Kurasawa M, Mishima K, Akaike N.

Pharmacology. 1994 Apr;48(4):226-33.

PMID:
8177909
45.
46.

Cerebral ischemia model with conscious mice. Involvement of NMDA receptor activation and derangement of learning and memory ability.

Himori N, Watanabe H, Akaike N, Kurasawa M, Itoh J, Tanaka Y.

J Pharmacol Methods. 1990 Jul;23(4):311-27.

PMID:
2164622

Supplemental Content

Loading ...
Support Center